Pi Coin Surges 10% as Capital Floods In and Bulls Take Control

Pi Coin rockets double-digits as money pours into the digital asset space

Bullish momentum builds

Capital inflows accelerate while buyer positions strengthen across the board. The 10% surge signals growing institutional confidence in alternative digital assets.

Market dynamics shift

Traditional finance veterans watch from the sidelines - still trying to figure out how to short innovation while missing the entire rally. Meanwhile, crypto natives keep stacking gains.

Digital assets continue proving they don't need Wall Street's permission to create wealth. The revolution isn't just being televised - it's being tokenized.

TipRanks Black Friday Sale

• Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
• Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off

In this article, we highlight the two companies, detailing the drugs in the lineup for a decision, the function of these medications, and how Wall Street is currently rating these stocks.

Be sure to click on any ticker for in-depth research before making portfolio decisions. The chart below provides insight into how these two companies compare.

– This is a Danish biopharma company that specializes in developing therapies for cancer and other rare diseases, such as conditions that affect the hormone-producing glands in the body. It is the Maker of Skytrofa, a once-weekly injection for children with low growth hormone, and Yorvipath, a drug that helps to restore the body’s calcium balance.

The FDA is set to decide on TransCon CNP, another once-weekly therapy by Ascendis, designed to promote bone growth in the body.

(KURA) – Kura is an American biopharma company that develops medications to target genetic drivers of cancer. Its leading product is Komzifti, a pill that helps treat a specific kind of blood cancer called acute myeloid leukemia (AML).

Kura is awaiting the FDA’s decision on Ziftomenib, a drug designed to treat AML.

Which Stock Offers the Most Upside?

Ascendis and Kura’s shares both currently have a Strong Buy consensus rating from analysts. However, in terms of upside potential, Kura’s shares comfortably lead, offering a massive upside of 136.20% at an average KURA price target of $26.88.

Ascendis’s shares with an average ASND price target of $260.15 offer about 23.13% upside.

.